Implementation of pharmacogenetics in clinical practice is challenging

Pharmacogenomics

Volumn 12, Issue 9, 2011, Pages 1231-1233

  Van Schie, Rianne M F ^a   De Boer, Anthonius ^a   Maitland Van Der Zee, Anke Hilse ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

clinical practice; implementation; pharmacogenetics

Indexed keywords

ABACAVIR; AZATHIOPRINE; CARDIOVASCULAR AGENT; COUMARIN; CYTOCHROME; WARFARIN;

CLINICAL PRACTICE; DNA DETERMINATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GENETIC SCREENING; GENOTYPE; HEALTH INSURANCE; HUMAN; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; PHARMACEUTICAL CARE; PHARMACOGENOMICS; POINT OF CARE TESTING; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

BIOMARKERS, PHARMACOLOGICAL; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80052938226     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.81     Document Type: Review

References (12)

1. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol. Diagn. Ther. 13(1), 1-9 (2009).
2. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008). (Pubitemid 351214284)
3. Relling MV, Gardner EE, Sandborn WJ et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3), 387-391 (2011).
4. van Schie RMF, Wadelius MI, Kamali F et al. Genotype-guided dosing of coumarin derivatives: the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009).
5. French B, Joo J, Geller NL et al. Statistical design of personalized medicine interventions: the Clarifcation of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11, 108 (2010).
6. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A et al. Reasons for non-response in observational pharmacogenetic research. Pharmacoepidemiol. Drug Saf. 18(8), 665-671 (2009).
7. Wilffert B, Swen J, Mulder H et al. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Pharm. World Sci. DOI: 10.1007/s11096-010-9446-1 (2010) (Epub ahead of print).
8. Swen JJ, Nijenhuis M, de Boer A et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89(5), 662-673 (2011).
9. Verhoef TI, Redekop WK, Darba J et al. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics 11(7), 989-1002 (2010).
10. van Schie RM, Wessels JA, le Cessie S et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur. Heart J. DOI: 10.1093/eurheartj/ehr116 (2011) (Epub ahead of print).
11. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
12. ® probes. Clin. Chim. Acta DOI: 10.1016/j.cca.2011.07.013 (2011) (In Press).